Drug Profile


Alternative Names: 4197X-RA; Monoclonal antibody ricin A

Latest Information Update: 20 Feb 2006

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Houston Biotechnology
  • Class Eye disorder therapies; Immunotoxins
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Cataracts

Most Recent Events

  • 18 May 2004 Suspended - Preclinical for Cataracts in Japan (unspecified route)
  • 31 Jan 2002 The collaboration between Scil Biomedicals and Medarex has ended
  • 31 Oct 2000 IDM has acquired certain economic interests in MDX RA as part of an expansion of its partnership with Medarex
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top